Måndag 2 Juni | 16:51:25 Europe / Stockholm

Prenumeration

2025-05-22 13:01:00

Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX basis. We believe the slack in growth is temporary, but we reduce the projected near- and medium-term sales of Brixadi slightly.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/